This promotional webinar series has been initiated and funded by Idorsia Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.

Beyond sleepless nights: managing chronic insomnia in adults

Sleep apnoea and chronic insomnia: two common disorders, one major burden

Explore the clinical overlap between sleep apnoea and chronic insomnia, and the cumulative burden these conditions place on patients. Dr Livingston will explore diagnosis, treatment pathways and practical strategies for managing both disorders with a personalised approach to care. He also looks at the role of QUVIVIQ®▼ (daridorexant) in the management of chronic insomnia in these patients.

This webinar will discuss QUVIVIQ (daridorexant), manufactured by Idorsia Pharmaceuticals.

1 CPD hour

Click here to view prescribing information and adverse event reporting information

QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.¹

1. QUVIVIQ Idorsia Pharmaceuticals Ltd, summary of product characteristics

schedule Thursday 17 September, 19:00–20:00

Speaker

Dr Cameron Livingston GP with Special Interest in Sleep Medicine

Title

First name

Last name

Please select an option

Practice / hospital name

Practice / hospital address

HCP registration number

Privacy Notice

Haymarket Media Group, the publisher of MIMS Healthcare Network takes your privacy seriously. Our Business brands and partners want to send you information and opportunities by email, phone and post. We believe we have a legitimate interest in using your details for marketing purposes, including promotional information from pharmaceutical companies, but if you do NOT wish to receive these messages, please click here.

I DON'T want to be kept updated with relevant information and opportunities from MIMS Healthcare Network and other Business brands via the following channels:

by email Required

by phone Required

We will use your details to ensure you receive messages that are relevant to you. You can stop receiving these messages from us at any time in the future, via the unsubscribe link on any email received or by contacting us directly. Please see our Full Privacy Notice.

By selecting "SIGN UP" you confirm that you agree to our Terms and Conditions statement.